Anti-CD22 therapy in acute lymphoblastic leukaemia

The Lancet Oncology

Volumn 13, Issue 4, 2012, Pages 329-331

  Hoelzer, Dieter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD22 ANTIGEN; CYTOTOXIC AGENT; DEXAMETHASONE; EPRATUZUMAB; IMMUNOCONJUGATED TOXIN; INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD22; MOXETUMOMAB PASUDOTOX; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; B CELL LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HUMAN; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN TARGETING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD22; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84859160486     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70010-4     Document Type: Letter

References (11)

1. Hoelzer D, Gokbuget N Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012, 26:25-32.
2. Raetz EA, Cairo MS, Borowitz MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 2008, 26:3756-3762.
3. Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011, 52:1098-1107.
4. Alderson RF, Kreitman RJ, Chen T, et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res 2009, 15:832-839.
5. von Stackelberg A Monoclonal antibodies in pediatric acute lymphoblastic leukemia. New agents for the treatment of acute lymphoblastic leukemia 2011, 221-267. Springer, New York. V. Saha, P. Kearns (Eds.).
6. Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, et al. Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (all) in children, adolescents and young adults: results from Children's Oncology Group (COG) study ADVL04P2. Blood 2011, 118(suppl):573. (abstr).
7. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012, published online Feb 21. 10.1016/S1470-2045(11)70386-2.
8. Wayne AS, Bhojwani D, Silverman LB, et al. A novel anti-CD22 Immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL). Blood 2011, 118(suppl):248. (abstr).
9. Dang NH, Smith MR, Offner F, et al. Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent/refractory follicular or 'aggressive' lymphoma. Blood 2009, 114(suppl):584. (abstr).
10. Hoelzer D Novel antibody-based therapies for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2011, 2011:243-249.
11. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011, 29:2493-2498.